FierceBiotech
@FierceBiotech
The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.
加入 December 2008
616 正在關注 102.7K 粉絲
The phase 3 Harbor trial of Novartis’ del-desiran has missed its primary endpoint, dealing a major blow to an asset that the Swiss drugmaker acquired in the $12 billion takeover of Avidity Biosciences.
顯示更多
